CYTK Cytokinetics Inc

$60.64

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 10/6/2025

About Cytokinetics Inc

Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.

Website: https://www.cytokinetics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1061983
Address
280 EAST GRAND AVENUE, ., SOUTH SAN FRANCISCO, CA, US
Valuation
Market Cap
$4.71B
P/E Ratio
nan
PEG Ratio
-0.42
Price to Book
60.31
Performance
EPS
$-5.26
Dividend Yield
Profit Margin
0.00%
ROE
-572.00%
Technicals
50D MA
$42.94
200D MA
$50.45
52W High
$68.76
52W Low
$32.74
Fundamentals
Shares Outstanding
119M
Target Price
$78.30
Beta
0.94

CYTK EPS Estimates vs Actual

Estimated
Actual

CYTK News & Sentiment

Oct 06, 2025 • Benzinga NEUTRAL
CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Cytokinetics ( NASDAQ:CYTK )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Oct 04, 2025 • Benzinga NEUTRAL
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CYTK - Cytokinetics ( NASDAQ:CYTK )
NEW YORK, Oct. 04, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. ( NASDAQ:CYTK ) between December 27, 2023 and May 6, 2025, both dates inclusive ( the "Class Period" ) , of the important November 17, ...
Oct 04, 2025 • Benzinga SOMEWHAT-BEARISH
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action Lawsuits - Cytokinetics ( NASDAQ:CYTK ) , Quanex Building Prods ( NYSE:NX )
NEW YORK, Oct. 04, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of V.F.
Oct 04, 2025 • Business Insider NEUTRAL
Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November ...
Oct 03, 2025 • Benzinga NEUTRAL
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Inc. Investors - Cytokinetics ( NASDAQ:CYTK )
LOS ANGELES, Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Cytokinetics, Inc., ( "Cytokinetics" or the "Company" ) ( NASDAQ:CYTK ) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive ( the "Class ...
Oct 03, 2025 • Benzinga NEUTRAL
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Cytokinetics ( NASDAQ:CYTK ) , Jasper Therapeutics ( NASDAQ:JSPR )
LOS ANGELES, Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Sentiment Snapshot

Average Sentiment Score:

0.103
50 articles with scored sentiment

Overall Sentiment:

Neutral

CYTK Reported Earnings

Feb 25, 2025
Dec 31, 2024 (Post market)
-0.09 Surprise
  • Reported EPS: $-1.26
  • Estimate: $-1.17
  • Whisper:
  • Surprise %: -7.3%
Nov 06, 2024
Sep 30, 2024 (Post market)
-0.11 Surprise
  • Reported EPS: $-1.36
  • Estimate: $-1.25
  • Whisper:
  • Surprise %: -8.8%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.25 Surprise
  • Reported EPS: $-1.31
  • Estimate: $-1.06
  • Whisper:
  • Surprise %: -23.6%
May 08, 2024
Mar 31, 2024 (Post market)
-0.19 Surprise
  • Reported EPS: $-1.33
  • Estimate: $-1.14
  • Whisper:
  • Surprise %: -16.7%
Feb 27, 2024
Dec 31, 2023 (Post market)
-0.41 Surprise
  • Reported EPS: $-1.38
  • Estimate: $-0.97
  • Whisper:
  • Surprise %: -42.3%
Nov 02, 2023
Sep 30, 2023 (Post market)
-0.61 Surprise
  • Reported EPS: $-1.35
  • Estimate: $-0.74
  • Whisper:
  • Surprise %: -82.4%
Aug 03, 2023
Jun 30, 2023 (Post market)
-0.19 Surprise
  • Reported EPS: $-1.34
  • Estimate: $-1.15
  • Whisper:
  • Surprise %: -16.5%
May 04, 2023
Mar 31, 2023 (Post market)
-0.18 Surprise
  • Reported EPS: $-1.38
  • Estimate: $-1.20
  • Whisper:
  • Surprise %: -15.0%
Mar 01, 2023
Dec 31, 2022 (Post market)
-0.24 Surprise
  • Reported EPS: $-1.45
  • Estimate: $-1.21
  • Whisper:
  • Surprise %: -19.8%

Financials